Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic
cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood …

Alloantigen expression on host antigen-presenting cells (APCs) is essential to initiate graft-versus-host
disease (GvHD); therefore, alloantigen expression on host target epithelium is …

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an
ultimate therapeutic target for AML. Here we identified T cell immunoglobulin mucin-3 (TIM-3…

Allogeneic hematopoietic stem cell transplantation (SCT) is a curative therapy for various
hematologic disorders. Graft-versus-host disease (GVHD) and infections are the major …

Background Quantitative RT-PCR (RT-qPCR) of nasopharyngeal swab (NPS) samples for
SARS-CoV-2 detection requires medical personnel and is time consuming, and thus is poorly …

Graft-versus-host disease (GVHD) continues to be a leading cause of morbidity and mortality
after allogeneic hematopoietic stem cell transplantation. Recent insights into intestinal …

We recently showed that IL-11 prevents lethal graft-versus-host disease (GVHD) in a murine
bone marrow transplantation (BMT) model of GVHD directed against MHC and minor …

Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term
outcomes after allogeneic bone marrow transplantation (BMT), but the pathophysiology of …

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response …